T2 relaxation times of 13C metabolites in a rat hepatocellular carcinoma model measured in vivo using 13C-MRS of hyperpolarized [1-13C]pyruvate

NMR in Biomedicine

Volumn 23, Issue 4, 2010, Pages 414-423

  Yen, Yi Fen ^a   Roux, Patrick Le ^a   Mayer, Dirk ^a,b   King, Randy ^b   Spielman, Daniel ^b   Tropp, James ^a   Pauly, Kim Butts ^b   Pfefferbaum, Adolf ^c,d   Vasanawala, Shreyas ^b   Hurd, Ralph ^a  

^a GE HEALTHCARE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SRI INTERNATIONAL   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

Alanine transaminase; Hepatocellular carcinoma; Hyperpolarized 13C; In vivo metabolic MRS; Liver metabolism; Morris HCC model; T2 relaxation time

Indexed keywords

HEPATOCELLULAR CARCINOMA; HYPERPOLARIZED; HYPERPOLARIZED 13C; IN VIVO METABOLIC MRS; IN-VIVO; MODEL T; MORRIS HCC MODEL;

BIOMARKERS; LIVER; METABOLISM; METABOLITES; RATS; SPIN POLARIZATION; TUMORS;

RELAXATION TIME;

ALANINE; LACTIC ACID; PYRUVIC ACID;

ANIMAL EXPERIMENT; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DIAGNOSTIC VALUE; LIVER CELL CARCINOMA; LIVER METABOLISM; MALE; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RAT; RELAXATION TIME;

ALANINE; ANIMALS; CARBON ISOTOPES; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; LIVER NEOPLASMS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PYRUVIC ACID; RATS; RATS, WISTAR;

RATTUS;

EID: 77951531563     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1481     Document Type: Article

References (43)

1. Schroeder MA, Atherton HJ, Ball DR, Cole MA, Heather LC, Griffin JL, Clarke K, Radda GK, Tyler DJ. Real-time assessment of Krebs cycle metabolism using hyperpolarized 13C magnetic resonance spectroscopy. FASEB J. (Epub) 2009; Mar 27.
2. Albers MJ, Bok R, Chen AP, Cunningham CH, Zierhut ML, Zhang VY, Kohler SJ, Tropp J, Hurd RE, Yen YF, Nelson SJ, Vigneron DB, Kurhanewicz J. Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res. 2008; 68(20): 8607-8615.
3. Gallagher FA, Kettunen MI, Day SE, Lerche M, Brindle KM. 13C MR spectroscopy measurements of glutaminase activity in human hepatocellular carcinoma cells using hyperpolarized 13C-labeled glutamine. Magn. Reson. Med. 2008; 60: 253-257.
4. Gallagher FA, Kettunen MI, Day SE, Hu DE, Ardenkjaer-Larsen JH, Zandt R, Jensen PR, Karlsson M, Golman K, Lerche MH, Brindle KM. Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. Nature 2008; 453(7197): 940-943. (Pubitemid 351832568)
5. Golman K, Petersson JS, Magnusson P, Johansson E, Akeson P, Chai CM, Hansson G, Må nsson S. Cardiac metabolism measured noninvasively by hyperpolarized 13C MRI. Magn. Reson. Med. 2008; 59: 1005-1013.
6. Kurhanewicz J, Bok R, Nelson SJ, Vigneron DB. Current and potential applications of clinical 13C MR spectroscopy. J. Nucl. Med. 2008; 49: 341-344.
7. Merritt ME, Harrison C, Storey C, Jeffrey FM, Sherry AD, Malloy CR. Hyperpolarized 13C allows a direct measure of flux through a single enzyme-catalyzed step by NMR. Proc. Natl. Acad. Sci. USA 2007; 104(50): 19773-19777.
8. Chen AP, Bok R, Zhang V, Xu D, Veeraraghavan S, Hurd RE, Nelson SJ, Kurhanewicz J, Vigneron DB. Serial hyperpolarized 13C 3D-MRSI following therapy in a mouse model of prostate cancer. In Proceedings of the 16th Annual Meeting of ISMRM, Toronto, Canada, 2008; 888.
9. Chen AP, Albers MJ, Cunningham CH, Kohler SJ, Yen YF, Hurd RE, Tropp J, Bok R, Pauly JM, Nelson SJ, Kurhanewicz J, Vigneron DB. Hyperpolarized C-13 spectroscopic imaging of the TRAMP mouse at 3T-Initial experience. Magn. Reson. Med. 2007; 58(6): 1099-1106.
10. Golman K, in't Zandt R, Lerche M, Pehrson R, Ardenkjaer-Larsen JH. Metabolic imaging by hyperpolarized 13Cmagnetic resonance imaging for in vivo tumor diagnosis. Cancer Res. 2006; 66(22): 10855-10860.
11. Day SE, Kettunen MI, Gallagher FA, Hu D-E, Lerche M, Wolber J, Golman K, Ardenkjaer-Larsen JH, Brindle KM. Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nature Med. 2007; 13(11): 1382-1387. (Pubitemid 350073590)
12. Golman K, Olsson LE, Axelsson O, Månsson S, Karlsson M, Petersson JS. Molecular imaging using hyperpolarized13C. Br. J. Radiol. 2003; 76(Spec No 2): S118-127.
13. Yen YF, Le Roux P, Bok R, Tropp J, Chen AP, Zhang VY, Zierhut ML, Albers MJ, Park I, Nelson SJ, Vigneron DB, Kurhanewicz J, Hurd RE. Apparent T2 of 13C-labeled metabolites in vivo. In Proceedings of the 16th Annual Meeting of ISMRM, Toronto, Canada, 2008; 1747.
14. Garwood M, DelaBarre L. The return of the frequency sweep: designing adiabatic pulses for contemporary NMR. J. Magn. Reson. 2001; 153: 155-177.
15. Silver MS, Joseph RI, Hoult DI. Highly selective 1/4 = 2 and 1/4 pulse generation. J. Magn. Reson.1984; 59: 347-351.
16. Baum J, Tycko R, Pines A. Broadband and adiabatic inversion of a two-level system by phase-modulated pulses. Phys. Rev. 1985; A 32: 3435-3447.
17. Hardy CJ, Edelstein WA, Vatis D. Efficient adiabatic fast passage for NMR population inversion in the presence of radiofrequency field inhomogeneity and frequency offsets. J. Magn. Reson. 1986; 66: 470-482.
18. Ugurbil K, Garwood M, Rath A. Optimization of modulation functions to improve insensitivity of adiabatic pulses to variations in B1magnitude. J. Magn. Reson. 1988; 80: 448-469.
19. Tannus A, Garwood M. Adiabatic pulses. NMR Biomed. 1997; 10: 423-434.
20. Pauly J, Le Roux P, Nishimura D, Macovski A. Parameter relations for the Shinnar-Le Roux selective excitation pulse design algorithm. IEEE Trans. Med. Imag. 1991; 10: 53-65.
21. Le Roux P, Gilles R, McKinnon G, Carlier P. Optimized outer volume suppression for single-shot fast spin-echo cardiac imaging. J. Magn. Reson. Imag. 1998; 8: 1022-1032.
22. Schulte RF, Taso J, Boesiger P, Pruessman KP. Equi-ripple design of quadratic-phase RF pulses. J. Magn. Reson. 2004; 166: 111-122.
23. Ravoet C, Bleiberg H, Gerard B. Non-surgical treatment of hepatocellubar carcinoma. J. Surg. Oncol. 1993; 3(Suppl.): 104-ill.
24. Venook AP. Treatments of hepatocellular carcinoma: too many options? J. Clin. Oncol. 1994; 12: 1323-1334.
25. Holland AE, Hecht EM, Hahn WY, Kim DC, Babb JS, Lee VS, West AB, Krinsky GA., Importance of Small (≤20-mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: evaluation and comparison with whole explanted liver. Radiology 2005; 237: 938-944.
26. Morris HP. Some growth, morphological, and biochemical characteristics of hepatoma 5123 and other new transplantable hepatomas. In Progress in Experimental Tumor Research, Karger, 1963; 3: 370-411.
27. Weber G. Introductory remarks on some basic concepts in neoplasia. Cancer Res. 1963; 23: 1471-1473.
28. Elwood JC, Lin Y-C, Cristofalo VJ, Weinhouse S, Morris HP. Glucose utilization in homogenates of the Morris hepatoma 5123 and related tumors. Cancer Res. 1963; 23: 906-913.
29. Weber G, Henry MC, Wagle SR, Wagle DS. Correlation of enzyme activities and metabolic pathways with growth rate of hepatomas. Adv. Enzyme Regul. 1964; 2:335-346.
30. Shonk CE, Morris HP, Boxer GE. Patterns of glycolytic enzymes in rat liver and hepatoma. Cancer Res. 1965; 25: 671-676.
31. Fields ALA, Wolman SL, Cheema-Dhadli S, Morris HP, Halperin ML. Regulation of Energy Metabolism in Morris Hepatoma 7777 and 78001. Cancer Res. 1981; 41: 2762-2766. (Pubitemid 11071809)
32. Morris HP, Wagner BP. 1965. Proceedings of the 8th International Congress on Cancer. Moscow, Russia, 1962, 1964. Acta Union Int. Contro. Cancer 1962, 1964; 20: 1364-1366.
33. Warburg O. On the origin of cancer cells. Science. 1956; 123(3191): 309-314.
34. Zierhut ML, Chen AP, Bok R, Albers MJ, Zhang V, Pels P, Tropp J, Park I, Vigneron DB, Kurhanewicz J, Hurd RE, Nelson SJ, Yen YF. Kinetic modeling of hyperpolarized 13c1-pyruvate metabolism using dynamic magnetic resonance spectroscopy. In Proceedings of the 15th Annual Meeting of ISMRM, Berlin, Germany, 2007; 366.
35. Weber G, Morris HP. Comparative biochemistry of hepatomas III. Carbohydrate enzymes in liver tumors of different growth rates. Cancer Res. 1963; 23: 987-994.
36. Pfab T, Stoltenburg-Didinger G, Trautner C, Godes M, Bauer C, Hocher B. The endothelin system in Morris hepatoma-7777: an endothelin receptor antagonist inhibits growth in vitro and in vivo. Br. J. Pharmacol. 2004; 141: 215-222.
37. Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, Thaning M, Golman K. Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR. Proc. Natl. Acad. Sci. USA. 2003; 100: 10158-10163.
38. Derby K, Tropp J, Hawryszko C. Design and evaluation of a novel dual-tuned resonator for spectroscopic imaging. J. Magn. Reson. 1990; 86(3): 645-651.
39. Henkelman RM. Measurement of signal intensities in the presence of noise in MR images. Med. Phys. 1985; 12(2): 232-233.
40. 13C-pyruvate. Molec. Imag. Biol. 2009; in press.
41. Kohler SJ, Yen Y, Wolber J, Chen AP, Albers MJ, Bok R, Zhang V, Tropp J, Nelson SJ, Vigneron DB, Kurhanewicz J, Hurd RE. In vivo 13 carbon metabolic imaging at 3T with hyperpolarized 13C-1-pyruvate. Magn. Reson. Med. 2007; 58(1): 65-69.
42. Peterson ET, Gordon JW, Kurpad KN, Fain SB, Rowland IJ. Probing the in vivo compartmentalization of hyperpolarized pyruvate using gadodiamide-induced T1 relaxation. In Proceedings of the 17th Annual Meeting of ISMRM, Honolulu, USA, 2009; 2417.
43. Michaelis L, Menten M. Die Kinetik der Invertinwirkung. Biochem. Z. 1913; 49: 333-369.